Background. Phospholipase A 2 receptor (PLA 2 R) is recognized as a target antigen in primary membranous nephropathy (MN); however, little is known about the potential contribution of α-enolase to the pathogenesis of MN.
Introduction
Membranous nephropathy (MN)-a major glomerular disease and common cause of adult nephrotic syndrome-is characterized by glomerular subepithelial IgG deposits [1] . Primary MN is predominantly associated with glomerular deposition of the IgG4 subtype [2] [3] [4] [5] [6] , whereas secondary MN is characterized by prevailing deposits of IgG1, IgG2, and IgG3 [6] [7] [8] . During the past decade, several breakthroughs have occurred with the identification of several candidate human antigens in MN. Wakui et al. identified anti-α-enolase antibodies in patients with primary or secondary MN [9] . In infants with MN, Debiec et al. detected anti-neutral endopeptidase antibodies that were produced by mothers who lacked this enzyme [10, 11] . Beck et al. demonstrated that IgG4 antibodies specific for M-type phospholipase A 2 receptor (PLA 2 R) were present in 6 glomerular eluates and serum from adult patients with primary MN [12] . Other candidate autoantigens in patients with primary MN include superoxide dismutase 2 (SOD2) and aldose reductase [13] . Debiec et al. reported that some patients who develop MN in early childhood had circulating anti-bovine serum albumin (BSA) antibodies and cationic BSA as a component of glomerular immune deposits [14] .
Interestingly, unlike other antibodies identified in patients with autoimmune MN, anti-α-enolase antibodies have been found in both primary and secondary MN. In the present study, we attempted to identify the epitope (s) recognized by anti-enolase autoantibodies, and we examined the potential relationship between anti-α-enolase antibodies and anti-PLA 2 R antibodies, and the glomerular deposition of α-enolase and PLA 2 R proteins in Japanese patients with primary and secondary MN.
Materials and methods
This study was approved by the Ethics Committee at Aichi Medical University.
Patients Characteristics
We included Japanese patients with MN who were admitted to Aichi Medical University Hospital and affiliated hospitals between 2003 and 2011. Diagnosis of MN 7 was based on light microscopy, immunofluorescence, and electron microscopy analyses of kidney biopsy specimens [15] . Primary MN was defined according to morphologic criteria after excluding known underlying diseases and drug exposure. Sera from 25 patients with primary MN, 20 patients with secondary MN, 44 patients with collagen diseases or severe infection, and 20 healthy subjects were stored at 80°C until use.
Sera from all patients with MN were obtained before steroid and immunosuppressive treatment with the approval of the institutional ethics committee. Patients characteristics are summarized in Table 1 . Complete remission was defined as urinary protein excretion of less than 300 mg/day as a result of therapeutic intervention (spontaneous remission?). Partial remission was defined as…….
Preparation of α-Enolase Deletion Mutants
We obtained sequence encoding full-length human α-enolase (433 amino acids; GenBank AK315417, Ensembl:ENSG00000074800). As a result of post-translational modification, human α-enolase is a 47-kDa glycoprotein. Complementary DNA (cDNA) cloning and production of fusion proteins were described elsewhere [16] . Briefly, full-length and truncated cDNA encoding human α-enolase ( Fig. 2 ) was amplified in polymerase chain reactions, and ligated to sequence encoding glutamine S-transferase 8 (GST) (GE Healthcare Bio-Sciences Corp., Piscataway, NJ). DNA was cloned into pGEX plasmids and transformed into JM109 cells (Promega, USA), and protein expression was induced using isopropyl-β-D-thiogalactopyranoside. After protein extraction from JM109 cells, tagged proteins were affinity purified using glutathione-Sepharose 4B (Amersham Pharmacia Biotech).
Western and Dot Blot Analysis
Please describe the WB and specify whether it was performed in reducing or non-reducing conditions. Nitrocellulose membranes (GE Healthcare, UK) were washed in PBS (Wako Pure Chemical Industries, Japan) containing 10 g/ml recombinant -enolase protein and 5% (w/v) skim milk (BD Difco, USA) for 60 minutes at room temperature. The membrane was washed three times with PBS containing 0.05% Tween (Katayama Chemical Industries, Japan), and incubated with patient serum at a dilution of 1:200. After three washes in PBS containing 0.05% Tween, the membrane was incubated with horseradish peroxidase-conjugated anti-human IgG antibodies at a dilution of 1:1000 (Sigma-Aldrich, USA). After three washes, reaction product on the membrane was visualized using an enhanced chemiluminescence system (ChemiLumit Kit, GE Health 9 Care, UK). Photographic images were obtained using an LAS-1000 system (FujiFilm Co., Japan). Image Reader Lite for LAS-1000 plus Ver. 1.3 (FujiFilm Co.) was used to capture the images, which were edited using Adobe Photoshop, when necessary.
Anti-PLA 2 R Antibodies
Anti-PLA 2 Rspecific autoantibody titers were measured as previously described based on indirect immunofluorescence in HEK 293 cells that were transiently transfected with full-length cDNA encoding PLA 2 R (Euroimmun) [17] . Antibody positivity was defined as positive staining at serum dilutions of at least 1/10. Negative results for anti-PLA 2 R antibodies were defined as an absence of detectable signals at an antibody dilution of 1/10. Antibody specificity was checked on Western blots under nonreducing conditions using glycoproteins extracted from normal human glomeruli after removing endogenous IgG. [18] .
Glomerular Deposition of α-Enolase and PLA 2 R Proteins
-enolase and PLA 2 R were detected in paraffin-embedded native biopsies under a confocal microscope using affinity-purified specific anti-rabbit -enolase (is the source Atlas?) and PLA 2 R antibodies (Atlas Antibodies, Stockholm, Sweden) followed by goat USA) as previously described [17] . Staining with only secondary antibodies produced negative results for all biopsies.
Statistical Analysis
Data were analyzed using Microsoft Excel software. Normally distributed variables were described as mean standard deviation and compared across primary and secondary MN using analysis of variance. Age, amount of urinary protein, and serum creatinine were compared using Student's t-test. MannWhitney U-tests (nonparametric) were used to compare results for anti--enolase antibody positivity in patients with MN and control subjects. All P-values are two tailed, with <0.05 considered statistically significant.
Results

Patients Characteristics
The study comprised 25 patients with primary MN, and 20 patients with secondary MN (seven patients had bucillamine-induced nephropathy and 13 patients had lupus nephritis World Health Organization type V). Patients characteristics are summarized in Table 1A and 
Detection of Anti--Enolase Antibody
We first examined whether sera from patients with MN contained antibodies specific for recombinant -enolase. Recombinant -enolase fragments were prepared as described in the Methods. Schematic representations of full-length -enolase cDNA and 10 different deletion mutants used in the present study are shown in 
Analysis of α-Enolase Epitopes in Patients with MN
We next examined the patients with circulating antibodies specific for human -enolase.
Recombinant -enolase fragments were prepared as described in the Methods Schematic representations of full-length -enolase cDNA and 10 different deletion mutants used in the present study are shown in Figure 1 
IgG Subclasses of Circulating Anti--Enolase Antibodies
We then characterized IgG subclasses of anti--enolase antibodies in both primary and secondary MN ( Figure 5 ). In primary MN, most antibodies appeared to be IgG1 or IgG4; 72% of patients being positive for at least one of these subclasses on dot blots. In secondary MN, however, IgG1 and IgG3 produced the strongest signals, with positive results observed in 75% of patients, contrasting very little or absent IgG4 reactivity.
Again, serum from each patient that immunoreacted with full-length -enolase also was positive with the N-and C-terminal fragments (amino-acid stretch 166 and 349433, respectively). These observations are in line with other data showing that subepithelial immune deposits in primary MN primarily contain IgG4 antibodies, whereas IgG1 and IgG3 subclasses are most common in deposits associated with secondary MN [15] .
Circulating Anti--Enolase Antibodies Before and After Treatment
We examined the effects of treatment on circulating antibodies specific for -enolase in a patient with primary MN, a patient with lupus MN, and three patients with bucillamine-induced MN, who all attained complete remission after treatment. We also assessed three patients with primary MN and one patient with lupus MN who failed to achieve complete remission despite therapy. Notably, circulating antibodies were no longer detected in any of the patients who reached complete remission ( Figure 6 ).
Among the 4 patients who failed to attain complete remission, antibody titers were markedly decreased in the patient with lupus MN, and in two of three patients with primary MN, and unchanged in the remaining patient ( Figure 6 ). IgG subclass analyses confirmed that the affected antibody titers were associated with IgG1 and/or IgG4 in primary MN, and IgG1 and IgG3 in secondary MN ( Figure 6 ).
Anti-PLA 2 R Antibody Hanna please revise the numbers
Twelve of 25 (48%) tested sera from patients with primary MN had anti-PLA 2 R antibodies Could be written like this: -Of the 12 PLA 2 R-positive patients, X were positive for anti--enolase, Y were negative. Of the 13 PLA 2 R-negative patients,……‖ Four of 16 (25%) patients also had anti-α-enolase antibody. Three patients with anti-PLA2R antibodies had no anti-α-enolase antibodies (Table 1A) . Six patients with anti-α-enolase antibodies were negative for anti-PLA 2 R antibodies, and three patients showed neither antibody. None of the 19 examined patients with secondary MN were positive for anti-PLA 2 R antibodies.
Glomerular Deposition ofα-Enolase and PLA 2 R Proteins Hanna please revise the numbers
In paraffin-embedded kidney biopsy specimens, confocal microscopy showed the presence of PLA 2 R in subepithelial deposits along glomerular capillary loops in 10 of 19 patients with primary MN. Eight of the 10 patients also had circulating anti-PLA 2 R 16 antibodies, but two had not (Figure 7 ). PLA 2 R was absent in the Z examined biopsy specimens from patients with lupus-and bucillamine-related MN (Figure 8 ). 
Discussion
Our study provides important data on immunopathology of MN. It first shows that circulating anti--enolase IgG4 antibodies, with or without IgG1 antibodies, were present in 72% of the patients with primary MN, while anti--enolase IgG3 antibodies, with or without IgG1 antibodies, were detected in 75% of those with secondary MN.
Circulating antibodies disappeared in the few tested patients undergoing complete remission. Second, we found that anti--enolase antibodies recognized both N-and C-terminal regions of -enolase, where they react with an epitope located in two short amino-acid stretches. Third, we showed a low prevalence (48%) of anti-PLA 2 R antibodies in this small cohort of Japanese patients with primary MN assessed before treatment, with four of 16 patients producing both antibodies (25%) (Hanna please revise the numbers), while we could not detect anti-PLA 2 α-Enolase is a 47-kDa glycoprotein [20] which catalyzes the dehydration of 2-phosphoglycerate to phosphoenolpyruvate, and usually exists as a cytoplasmic multienzyme complex with other glycolytic enzymes, such as pyruvate kinase, phosphoglycerate mutase, and muscle creatine kinase [21] . Different cellular localizations of potential MN auto-antigens are seen under normal physiologic conditions. While neutral endopeptidase and PLA 2 R are expressed on cell surface of podocytes [12, 22] , aldose reductase and SOD2 are cytoplasmic/mitochondrial enzymes which can be enhanced at the cell surface after oxidative stress [13] . Similarly, -enolase is usually cytoplasmic in renal tissue although it is strongly expressed on the cell surface of tubular epithelium [23] where it may function as a plasminogen receptor [24] . Cytoplasmic α-enolase can appear at the cell surface following two pathways: the first is secretory pathway, the second involves binding of α-enolase released from damaged cells (ref????). Enhanced expression at the cell surface may thus occur after initial immune complex injury and complement activation.
Although circulating anti-α-enolase antibodies were commonly found, unlike PLA 2 R α-enolase was never detected in subepithelial immune deposits, in contrast with the observations made by Bruschi et al.(19) . This finding suggests that anti-α-enolase 20 antibody does not directly contribute to the formation of subepithelial immune deposits and resulting complement activation. We cannot, however, exclude a pathogenic role for anti-α-enolase antibodies through binding to endothelial or podocyte cell surface, and We found that the prevalence of anti-PLA 2 R antibodies in previously untreated patients (48%) was lower than that previously reported Caucasian, African, and Chinese cohorts where it was comprised between XX and YY % [12, 26 add Hoxha and Svobodova], suggesting an effect of the genetic background (Hanna, prevalence of HLA-DQA1 in the Japanese?).
In conclusion, circulating anti-α-enolase antibody was detected in about 70% of Lower left: the photograph shows dot blotting, with positive results for the following human -enolase fragments form above -a‖ to -k‖. 29 Upper and lower right: When serum from a normal control subject was used, no signals were observed on Western blots (upper right) or dot blotting (lower right). 
